bpc 157 nervous system Peptide therapy with pentadecapeptide in traumatic nerve injury Naples, FL Physician Highlights Benefits

Quick shipping, informed medical providers

Quality control issues present practical safety concerns beyond inherent peptide properties

What they found: Favorable safety profile , no serious adverse events at doses up to 100 g/kg Preliminary efficacy signals positive The program stopped before Phase 3 for unknown commercial reasons (the program passed through several sponsor rotations and no one ultimately carried it through) Why it matters: These are the only published clinical data in humans that we have

From the small-batch synthesis of our peptides to the meticulous third-party testing we conduct, every step is about eliminating variables and ensuring reliability